Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aurelius Health Group vs Human+

Aurelius Health Group
Graded #311

Higher grade

vs+1
Human+
Graded #333

Lower grade

The verdict

Aurelius Health Group takes it — 60.8/100 to 59.8/100, but only just.

Aurelius Health Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aurelius Health Group is a telehealth platform built around compounded tirzepatide microdosing — a low-dose dual GIP/GLP-1 protocol rather than standard full-dose therapy — with optional NAD+, L-carnitine,… Human+ is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAurelius Health Group +9
54
45
Dose & formulationAurelius Health Group +12
52
40
Clinical oversightHuman+ +7
76
83
Labs & monitoringHuman+ +3
63
66
FulfillmentHuman+ +29
61
90
Contract termsAurelius Health Group +20
61
41
Aurelius Health Group · left barHuman+ · right bar

The numbers

MetricAurelius Health GroupHuman+
WeighScore60.8/10059.8/100
GradeCC
Scorecard rank#311#333
SemaglutideNot disclosedNot disclosed
Tirzepatide$199/mo (microdose tier, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Aurelius Health Group

Graded #311 · C

Strengths

  • Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
  • LegitScript Certified
  • Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
  • Unusually candid about the limited evidence base for microdosing

Where it loses points

  • The advertised $89 is a first-month new-patient rate; every month after it is $199
  • This is a 1 mg microdose programme and nothing else — no labelled therapeutic dose is sold, so it is not an alternative to a full-dose prescription
  • No state count is published, only 'most US states', confirmed at intake
  • The site's own comparison table calls 2.4 mg/week the tirzepatide 'standard full dose'; 2.4 mg is the semaglutide maintenance dose, and tirzepatide is labelled 2.5-15 mg/week
  • Compounded tirzepatide is not an FDA-approved finished product
Human+

Graded #333 · C

Strengths

  • Cost-transparent model: a flat monthly membership with prescriptions billed at pharmacy-wholesale cost instead of marked up
  • Available via telehealth in all 50 states
  • Filled by US 503A compounding pharmacies and reviewed by board-certified US-licensed clinicians
  • Fast, fully online 5-minute intake with provider review often within hours; discreet plain packaging
  • Covers weight loss plus hair, sexual wellness, mental health, and labs under one membership

Where it loses points

  • Specific GLP-1 medications and pricing are not published — you only see them after starting the intake
  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • LegitScript certification is shown only as a self-hosted badge; no verifiable LegitScript seal was found
  • Minimal public-facing site and a flat membership fee on top of the medication cost

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard